ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

A PATHOLOGICAL STUDY ON BORDERLINE OVARY TUMORS

AUTHORS:

Dr Toheed Rehman, Dr Khalid Hassan, Dr Wahid Gul

ABSTRACT:

Objective: The aim of this study is to describe occurrence and treatment of BOTs (Borderline Ovarian Tumors) in under developing countries like Pakistan. Methodology: It is an observational study of patients suffering from borderline ovarian tumors, for the duration of 10 years from 2008 to 2018 at Lady Reading Hospital Peshawar. This research work includes observation of types, characteristics and cure of BOTs. We retrieved and classified the calculated data. Results: We identified 86 patients suffering from borderline ovarian tumors with an average age of thirty-five years. According to our research, 42 patients were suffering from serous borderline ovarian tumors, 43 patients were suffering from mucinous borderline ovarian tumors and one patient was suffering from mixed typed. We categorized patients by the usage of international federation of gynecology and obstetrics (FIGO) standards. The complete removal of tumor occurred in 70 patients. There were 43 patients, who experienced FPS (fertility preserving surgery). After the duration of 31.50 months, seventy-three patients were having no disease. There was reappearance of disease in thirteen patients. The factors responsible for recurrence of invasive tumors are; having age more than 40 years, partial surgery and current stage of disease. Conclusion: Although BOTs is less harmful disease, there is possibility of recurrence in patients having age more than 40 years, not-completed surgery or higher stage at the time of treatment. FSS is considerable, in case of young patients. To minimize the relapse of the disease removal of tumor and treatment for a long time is necessary. KEY WORDS: Borderline Ovarian Tumors, Fertility Sparing Cancer, Fertility Preserving Surgery, Chemotherapy, Radiotherapy.

FULL TEXT

Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.